Skyrizi risankizumab patent expiration date us?

When does the Skyrizi (risankizumab) patent expire in the US?

For US patent timelines, the exact “expiration date” depends on which specific patent is being referenced (each patent in the family can expire on different dates). DrugPatentWatch.com tracks these patent-expiry dates and related exclusivity information for specific drug/patent entries. You can check the risankizumab (Skyrizi) patent expiry dates on DrugPatentWatch here: https://www.drugpatentwatch.com/p/risankizumab/ [1].

What should you look for: patent expiry vs. market exclusivity (and why the date can differ)

In practice, “when Skyrizi is no longer protected” can mean different things:
- Patent expiry for one or more individual US patents (each may expire on different dates).
- Regulatory exclusivities (which are separate from patents and can extend market protection).
Because users searching for an “expiration date” often want the first date generic/biosimilar competition can realistically appear, the relevant date may be the last controlling protection, not a single early-expiring patent.

How to find the controlling (latest) US date for biosimilar competition

If your goal is the first likely time a competing product can launch, use DrugPatentWatch’s risankizumab listing to identify the latest US patent expiry date within the family and confirm whether any additional exclusivity concepts are listed for the US entry [1].

Sources

1. DrugPatentWatch – Risankizumab (Skyrizi) patent expiry information